Formation Bio
Asset-licensing biotech that uses AI to speed drug development from license to trial.
The call
Formation Bio has real deals and real dosing speed, but the AI edge it charges a premium for is the exact thing Novo Nordisk, Sanofi, and OpenAI are now building in house.
Formation Bio is a young company that uses artificial intelligence to find and develop new drugs faster, then sells the rights to bigger pharmaceutical companies like Sanofi. The company has some real deals and early clinical results, but its main selling point, that AI gives it a special advantage, is not actually locked down. Competitors like Novo Nordisk, Sanofi, and Eli Lilly are all building their own AI drug-discovery tools, and AI companies like OpenAI are now selling these same capabilities directly to big pharma. The one thing that could change this picture is if Formation's drugs start succeeding in human trials faster or better than rivals' AI-discovered drugs, but so far no AI-discovered drug has been approved by regulators, so the real-world proof of this whole approach remains unwritten.
Why
01
AI pressure: OpenAI. OpenAI helped build Formation's own Muse tool, then sold similar AI directly to Novo Nordisk, undercutting the differentiation. Could AI do the core job? Yes, likely.
02
Bigger players: Novo Nordisk, Sanofi, Eli Lilly. Novo Nordisk signed an enterprise-wide OpenAI deal targeting full integration by end 2026, aiming to close the speed gap Formation sells. Could a giant copy it? Yes, easily.
03
What protects it. Regulatory sponsor-of-record role and signed licensing deals like the €545M Sanofi pact give it real assets big pharma can't just copy overnight.
What would change this call
Formation Bio announces a new equity round (flat, down, or up) in the next 6 to 9 months. Would show whether investors still pay a premium for its AI-native pharma narrative.
BLKR201 Phase 1 readout, expected early 2027. Would test whether its five-month deal-to-dosing speed translates into real clinical results.
Novo Nordisk or Sanofi publicly reports in-house AI drug-development speed matching Formation's cycle times. Would show incumbents closing the operational gap Formation claims as its edge.
BLKR201 Phase 1 readout, expected early 2027. Would test whether its five-month deal-to-dosing speed translates into real clinical results.
Novo Nordisk or Sanofi publicly reports in-house AI drug-development speed matching Formation's cycle times. Would show incumbents closing the operational gap Formation claims as its edge.
Key numbers
- €545M Sanofi gusacitinib deal
- $1.7B valuation on ~$39.2M ARR
- No priced round in 25+ months
Named risks
- No new priced funding round confirmed in 25 months as of mid-2026, signaling possible valuation pressure.
- Core AI-native trial-operations differentiation is copyable and being adopted by big pharma incumbents.
- Sector-wide, no AI-discovered or AI-developed drug has reached FDA approval as of June 2026.
- Revenue model concentrated in out-licensing deals dependent on partner milestone payments.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Novo Nordisk | gaining on | Signed enterprise-wide OpenAI deal April 14, 2026, targeting full AI integration by end-2026 |
| OpenAI | gaining on | Co-built Muse with Formation Bio, now selling similar capability directly to Novo Nordisk as of April 2026 |
| Sanofi | contesting | Both licensing partner (€545M deal, June 2025) and parallel builder of in-house AI-pharma programs |
| Miles Wang's new startup | gaining on | Ex-OpenAI researcher raising $2B valued AI drug discovery startup as of July 14, 2026 |
| Xaira Therapeutics, Insitro, Insilico Medicine | contesting | AI-native pharma peers competing for licensing deals and drug discovery positioning through 2026 |
Questions people ask
- Is Formation Bio profitable in 2026?
- Formation Bio has not disclosed profitability. Third-party estimates put revenue near $39.2M ARR as of September 2025 against an estimated $1.7B valuation. The company monetizes mainly through out-licensing deals, such as the up to €545M Sanofi gusacitinib deal signed June 23, 2025.
- Who owns Formation Bio?
- Formation Bio is privately held and venture-backed, with no parent company. Its Series D of $372M closed June 27, 2024, led by Andreessen Horowitz with Sanofi, Sequoia, and Thrive Capital participating. No new priced funding round has been publicly confirmed since then as of mid-2026.
- Could AI replace Formation Bio's business model?
- Formation Bio's core edge is AI-driven trial operations, the same capability big pharma is now building in-house. Novo Nordisk signed an enterprise-wide OpenAI partnership on April 14, 2026 targeting full integration by end-2026, directly threatening the operational speed advantage Formation Bio sells.
- Who is Formation Bio's biggest competitor?
- Formation Bio competes with AI-native peers Xaira, Insitro, and Insilico Medicine, but the bigger threat is big pharma itself: Novo Nordisk's April 2026 OpenAI deal and Sanofi's own AI push are building similar AI trial-operations capability in-house.
- What is Formation Bio's valuation?
- A third-party estimate from Getlatka places Formation Bio's valuation near $1.7B as of November 27, 2025, following its $372M Series D closed June 27, 2024 led by Andreessen Horowitz. The company has not officially disclosed a post-Series D valuation.
- Has Formation Bio gotten an AI-discovered drug approved by the FDA?
- No. As of June 26, 2026, no AI-discovered or AI-developed drug has received FDA approval industry-wide. Formation Bio's most advanced pipeline asset, BLKR201, dosed its first Phase 1 participant on June 8, 2026, with a readout expected in early 2027.
Timeline
- 2026-07-15Joined Illumina's Billion Cell Atlas alliance with AstraZeneca, Merck, Eli Lilly
- 2026-07-14Ex-OpenAI researcher Miles Wang reportedly raising $2B AI drug discovery startup
- 2026-06-08Dosed first Phase 1 participant in BLKR201 trial, five months after in-licensing
- 2026-04-14Novo Nordisk announced enterprise-wide OpenAI partnership for drug discovery
- 2026-01Licensed miR-124 activator (autoimmune) from CTFH
- 2025-12In-licensed BLKR201/LNK01006 from Lynk Pharmaceuticals via subsidiary Bleecker Bio
- 2025-07-29Licensed first-in-class Anti-CD226 monoclonal antibody program, now RVW101
- 2025-06-23Out-licensed gusacitinib to Sanofi for up to €545M via subsidiary Libertas Bio
- 2024-11-12Launched Muse, AI patient-recruitment tool built with OpenAI and Sanofi
- 2024-06-27Closed $372M Series D led by Andreessen Horowitz
Revision history
21 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Formation Bio Raises $372M in Series D (2024-06-27)
- How Much Did Formation Bio Raise? (2025-05-08)
- Formation Bio - Headcount, Funding & Open Jobs (2026-06-20)
- $39.2M ARR, $1.7B Valuation (2025-11-27)
- Formation Bio Company Profile
- Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (2026-06-09)
- Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (2026-06-08)
- Sanofi signs $626M deal to explore Formation's JAK/SYK inhibitor (2025-06-23)
- Introducing Muse (press archive listing) (2026-06-08)
- AI-Native Formation Bio Licenses Monoclonal Antibody (2025-07-29)
- Formation Bio collaborates with Sanofi and OpenAI to Introduce Muse (2024-11-12)
- Novo Nordisk Partners with OpenAI for Drug Discovery (2026-04-14)